MINNEAPOLIS, Minnesota—Reprise Biomedical, Inc., an innovator in medical biotechnology for wound care, announced the Centers for Medicare and Medicaid Services (CMS) has assigned a Level II Healthcare Common Procedure Coding System (HCPCS) code to its Miro3D wound matrix, effective Oct. 1, 2023.
Miro3D is a three-dimensional porcine-derived acellular graft designed to create a protective environment for wounds, specifically for use in cases requiring coverage of and conformance to intricate, tunneling and irregular wound beds. Available in four sizes, Miro3D features a consistent two-centimeter-thick porous sheet scaffolding structure. When hydrated, Miro3D softens slightly, adapting well to various wound bed shapes and can be fixated to surrounding tissue using preferred methods such as sutures or staples.
“At the core of Reprise Biomedical’s product portfolio lies Miro3D—a completely unique three-dimensional wound care solution,” said Carrie Powers, CEO of Reprise Biomedical. “The three-dimensional sheet scaffolding structure of Miro3D, which can be tailored to fit wound sizes through trimming or cutting, is transforming the treatment landscape for deep and tunneling wounds, diabetic foot ulcers and other advanced wound conditions."
CMS has assigned HCPCS Level II code A2025, ‘Miro3d, per cubic centimeter,’ to Miro3D. This new Level II HCPCS code permits health care providers to bill Medicare and other insurance carriers for Miro3D, thereby making Miro3D more accessible to patients across the country.
